The viral mitochondrial inhibitor of apoptosis (vMIA) encoded by the human cytomegalovirus exerts cytopathic effects and neutralizes the proapoptotic endogenous Bcl-2 family member Bax by recruiting it to mitochondria, inducing its oligomerization and membrane insertion. Using a combination of computational modeling and mutational analyses, we addressed the structure-function relationship of the molecular interaction between the protein Bax and the viral antiapoptotic protein vMIA. We propose a model in which vMIA exhibits an overall fold similar to Bcl-X L . In contrast to Bcl-X L , however, this predicted conformation of vMIA does not bind to the BH3 domain of Bax and rather engages in electrostatic interactions that involve a stretch of amino acids between the BH3 and BH2 domains of Bax and an a-helical domain located within the previously defined Bax-binding domain of vMIA, between the putative BH1-like and BH2-like domains. According to this model, vMIA is likely to bind Bax preferentially in its membraneinserted conformation. The capacity of vMIA to cause fragmentation of the mitochondrial network and disorganization of the actin cytoskeleton is independent of its Baxbinding function. We found that D131-147 vMIA mutant, which lacks both the Bax-binding function and cell-death suppression but has intact mitochondria-targeting capacity, is similar to vMIA in its ability to disrupt the mitochondrial network and to disorganize the actin cytoskeleton. vMIAD131-147 is a dominant-negative inhibitor of the antiapoptotic function of wild-type vMIA. Our experiments with vMIAD131-147 suggest that vMIA forms homooligomers, which may engage in cooperative and/or multivalent interactions with Bax, leading to its functional neutralization.
Introduction
Human cytomegalovirus (CMV), a member of the Herpesviridae family, infects a large segment of the human population establishing life-long latent infection. CMV has evolved multiple strategies in evading the immune system of the host, such as encoding chemokine decoy receptors UL33, UL78, US27, US28, Fc receptors gpTRL11.IRL11, gpUL119-118 and proteins that subvert natural killer cell responses UL16, gpUL40 (Michelson, 2004) . CMV does not cause overt clinical disease in immunocompetent individuals, but can cause severe illness in utero, in neonates, and in patients with inherited, acquired or iatrogenic immunodeficiency. Persistent CMV infection can enhance the tumorigenic and invasive properties of human neuroblastoma cells in culture (Hoever et al., 2005) , while reducing their propensity to undergo apoptosis (Terrasson et al., 2005) . According to one group, CMV genes or proteins are expressed in some tumors, for instance in colon (Harkins et al., 2002) and prostate carcinoma (Samanta et al., 2003) , but at present it is not yet clear if CMV exerts any co-oncogenic effects (Froberg, 2004) .
CMV encodes at least two antiapoptotic proteins, namely the viral inhibitor of caspase-8 activation, vICA (pUL36) ) and the viral mitochondria-localized inhibitor of apoptosis, vMIA (pUL37x1) (Goldmacher et al., 1999) . In addition, CMV causes the accumulation of DNp73a, a host-encoded inhibitor of p53 and p73 (Terrasson et al., 2005) and stimulates the antiapoptotic phosphatidylinositol 3,4,5 triphosphate kinase pathway (Smith et al., 2004) . vMIA protects CMV-infected cells from apoptosis in the late phase of the viral life cycle (Reboredo et al., 2004) , and vMIA-deficient/vICA-deficient CMV cannot replicate (because it kills the infected cells prematurely) unless it infects cells that overexpress a Bcl-2-like apoptosis inhibitor (Reboredo et al., 2004) . A laboratory strain of vICA-expressing/vMIA-deficient CMV can replicate on human cells (McCormick et al., 2005) , but a freshly isolated clinical strain of CMV encoding functionally active vICA loses its replication ability upon knocking out vMIA expression, suggesting that at least in some clinical CMV strains, vMIA is indispensable for viral replication (Jurak and Brune, 2006) . The vMIA protein is largely confined to the mitochondrial compartment, where it physically interacts with the protein Bax, recruiting it to mitochondria while neutralizing its proapoptotic function (Arnoult et al., 2004; Poncet et al., 2004) . As vMIA loses its antiapoptotic action in Bax-deficient cells (Arnoult et al., 2004) , it appears that vMIA exerts its antiapoptotic function solely by neutralizing Bax.
In addition to cell death suppression, there is evidence that vMIA interacts with the adenosine triphosphate (ATP) synthasome composed by the adenine nucleotide translocase, the F 1 F 0 ATP synthase and the mitochondrial phosphate carrier (Goldmacher et al., 1999; Vieira et al., 2001) . Through the inhibition of the phosphate carrier, vMIA causes a reduction of mitochondrial ATP generation and disorganization of the actin cytoskeleton, which may contribute to the cytopathic effects of vMIA (Poncet et al., 2006) .
Bax (along with Bak) is a key regulator of the apoptotic mitochondrial signal pathway (Wei et al., 2001) . Bax is a member of the Bcl-2 family, a group of proteins that share several distinct Bcl-2 amino-acid sequence homology (BH) domains. Several antiapoptotic members of this family, such as Bcl-2 and Bcl-X L , contain four BH domains (BH1, BH2, BH3 and BH4) and are thought to inhibit apoptosis mainly by preventing mitochondrial outer membrane permeabilization (MOMP) (Green, 2005) , (one of) the decisive step(s) of the apoptotic process (Galluzzi et al., 2006) . The proapoptotic multi-domain proteins of this family, Bax and Bak, carry three BH domains (BH1, BH2 and BH3) and facilitate MOMP. While Bak is constitutively loosely associated with the outer mitochondrial membrane, Bax is usually found as a monomer in the cytoplasm of healthy non-apoptotic cells (Wolter et al., 1997) . Apoptotic stimuli cause transcriptional induction and/or post-transcriptional modification of BH3-only proteins, which in turn activate Bax and/or Bak. The activation of Bax or Bak leads to their full insertion into the outer mitochondrial membrane, oligomerization and formation of supramolecular pores that allow for the release of soluble intermembrane proteins into the cytoplasm (Wei et al., 2001; Reed, 2006) . Bcl-2 and Bcl-X L prevent activation of Bax and Bak, either indirectly (by binding and inhibiting BH3-only proteins) or directly (by binding Bax and Bak) (Danial and Korsmeyer, 2004) . The crystal or nuclear magnetic resonance (NMR) structures of several Bcl-2 family proteins have been reported (Muchmore et al., 1996; McDonnell et al., 1999; Suzuki et al., 2000; Garcia-Saez et al., 2004) and physicochemical models explaining protein-protein interactions among Bcl-2 family members have been proposed (Sattler et al., 1997; Day et al., 2005) .
The primary structure of vMIA (163 amino acids, aa) has no obvious sequence identity with any of the Bcl-2 family members. vMIA contains two domains, a Nterminal mitochondrial localization sequence (MLS, aa 5-34) that does not undergo proteolytical removal (Mavinakere et al., 2006) and the Bax-binding domain (BBD, aa 115-147) (Arnoult et al., 2004; Poncet et al., 2004) . These domains are together necessary and sufficient for vMIA-mediated cytoprotection, as determined by deletion mapping (Goldmacher et al., 1999 (Goldmacher et al., , 2005 , and are highly conserved among all tested clinical viral isolates (Hayajneh et al., 2001) . The three-dimensional structure of vMIA has not been yet established by either NMR or crystal structure analysis.
Based on these premises and incognita, we decided to refine the analysis of the structural basis of the vMIABax interaction. Here, we report the amino-acid segments within vMIA and Bax that are critical for vMIA-Bax complex formation and propose a theoretical model structure of vMIA and of its interaction with Bax. This study is the first step towards the design of drugs targeting the vMIA-Bax interaction.
Results
Mapping of amino-acid residues in vMIA interacting with Bax The BBD of vMIA is confined to the aa 115-147 segment (Arnoult et al., 2004; Poncet et al., 2004) . We performed systematic deletion of penta-, hepta-or nonapeptide motifs from this domain ( Figure 1a ) and transfected these vMIA deletion mutants (D115-123, D124-130, D131-135, D136-140, D141-147) into control cells. When expressed at comparable levels (Figure 1b) , all mutants colocalized with mitochondrial markers such as the core 2 subunit of the respiratory chain complex III and mediated mitochondrial fragmentation ( Figure 1c ). Upon co-transfection of these vMIA mutants and Bax-green fluorescent protein (GFP), all but one recruited Bax-GFP to mitochondria, leading to an overlap of the Bax-GFP fluorescence with the immunofluorescence staining of the Myc epitope at the C-terminus of vMIA. The only vMIA mutant that failed to colocalize with Bax-GFP was vMIAD136-140 ( Figure 2a ). When we investigated the interaction between these vMIA constructs and endogenous Bax, we found again that the mutants D115-123, D124-130, D131-135 and D141-147 but not D136-140 co-immunoprecipitated with Bax ( Figure 2b ). In accord, the D115-123, D124-130, D131-135 and D141-147 mutants were similar to wild-type (WT) vMIA in their ability to inhibit apoptosis induced by either CD95 crosslinking (Figure 2c ) or addition of the tyrosine kinase inhibitor staurosporine (STS) (Figure 2d ), while D136-140 failed to suppress apoptosis (Figure 2c and d) . Hence, we can expect that one or several amino acids between residues 135 and 141 of vMIA might be essential for its interaction with Bax and apoptosis inhibition. Amino acids 138-140 arginine, arginine, histidine (RRH) are positively charged, and their joint replacement by alanine residues (R138A, R139A, H140A) (Figure 3a ) also abolished the antiapoptotic activity of vMIA (Figure 3b and c) under conditions in which the replacement of individual amino acids in the RRH motif failed to affect the antiapoptotic activity of vMIA (Figure 3c ). Thus, this triple amino-acid substitution (R138A, R139A and H140A) has a similar functional impact on vMIA as a mutation affecting a pair of amino acids with opposite charges (R127A and E128A) close to E128, which has been implicated in the interaction with Bax (Arnoult et al., 2004; Figure 3c ). Accordingly, the triple amino-acid substitution abolished the interaction of vMIA with endogenous Bax (Figure 3d ), exactly as does the double mutation (R127A, E128A) (Figure 3e ). Altogether, these data identify a stretch of positive charged amino acids (RRH in positions 138-140) that participate in the interaction of vMIA with Bax as well as in apoptosis inhibition.
Molecular modeling of vMIA and vMIA-Bax interaction
Although vMIA and Bcl-X L exhibit only a low degree of amino-acid sequence identity, the primary sequences of vMIA and Bcl-X L could be aligned based on secondary structure predictions (Figure 4a ). vMIA and Bcl-X L align particularly well within the a-helical Bcl-2 homology BH domains, in particular BH2 and BH3 (Figure 4a ). The predicted structure of vMIA shows a predominant alpha fold with an orthogonal bundle-like architecture. Similar to Bcl-X L , vMIA is predicted to contain eight a-helices (V4-S21, K42-V60, D62-N65, L78-E92, E98-D118, G124-R138, L143-R147 and R149-H155) (Figure 4b ). The molecular model of vMIA compared to the crystal structure of Bcl-X L suggests that the stabilizing inter-domain interactions, observed in the Bcl-X L structure, are conserved in vMIA.
We performed computerized docking experiments to predict the interface mediating the interaction between vMIA and Bax, using two published Bax structures, namely the structure of soluble Bax (Suzuki et al., 2000) (PDB access code 1F16) and a hypothetical structure of membrane-inserted Bax (Annis et al., 2005) . Model A, calculated for the interaction between vMIA and soluble Bax is based on a dense cluster of top-scored solutions, obtained by rigid docking calculations. The recognition process between vMIA and Bax would involve portions of BH1-like, BH2-like and the inter-BH1-like/BH2-like domain on vMIA, and the whole BH3 domain of Bax (Figure 5a ). More precisely, vMIA would participate in the interface with two amino-acid segments encompassing its fourth and sixth a-helices: A77-E92 and S123-Q145. The counterpart on Bax would be made up by its second a-helix (D53-S72) and a stretch enclosing the turn between its eighth and ninth a-helices (S163-I175). Several stabilizing interactions can be found in the putative interface. Specifically, salt bridges are predicted between E61 on Bax and K135, R138 on vMIA, between R65 on Bax and E81, E128 on vMIA, between D68 on Bax and R127 on vMIA. In addition, the side chain of E81 on vMIA would be hydrogen-bonded to the main chain NH group of W170 on Bax (Figure 5a ). Model B, calculated for the interaction between vMIA and a hypothetical structure of membrane-inserted Bax, predicts the involvement of relatively small protruding surface areas that are 'non-classical' in the sense that none of the amino acids predicted to participate in the interaction is located in a BH domain. Rather, charged amino acids (R127, E128 and R138) located within an a-helical bundle of vMIA located between its BH1-like and BH2-like domains would dock to their inversely charged interactors (R89, E90 and D98) within the a4 domain of Bax, driven by electrostatic forces (Figure 5b ). Computerized comparisons of the two models indicate that model B has a better surface complementarity score (À276 vs À210; the more negative the better) when compared to model A. Similarly, the van der Waals interaction energy between the two proteins is more favorable for model B than for model A (À217.7 vs À189.2; the more negative the better). In addition, empirical scoring using level pair potentials (Moont et al., 1999) , suggests that the interface in model B has a higher likelihood than the one in model A. Taken together, these results indicate that model B is energetically and physically preferred over model A. Both models suggest that precise domains within the vMIA molecule (the RRH motif at aa 138-140 and the RE dimer at aa 127-128) participate in the interface. However, the two models predict that rather distinct domains of the Bax molecule would engage in the interaction with vMIA. We subsequently undertook to evaluate both models by selective amino-acid substitutions within the Bax protein.
Mutational analysis of the Bax-vMIA interaction Model A predicts the involvement of the BH3 domain of Bax in the Bax-vMIA interface. We generated mutations of three charged residues within the BH3 domain of Bax-GFP (E61, R65 and D68), replacing them either with neutral alanines or with the corresponding residues contained in the BH3 domain of Bak (which does not interact with vMIA) (Arnoult et al., 2004; Figure 6a) . Transient transfection produced similar expression levels of these mutants (Figure 6b ). We then compared the ability of these constructs to abolish the mitochondrial transmembrane potential (DCm) (Figure 6c ), and to increase the permeability of cells to propidium iodide (PI) as indicators of apoptotic cell death (Figure 6d ). As Figure 6e ). Immunoprecipitation experiments showed that vMIA could interact with all the BH3 mutants of Bax, suggesting that BH3 domain of Bax does not participate in the interaction with vMIA and hence invalidating model A (Figure 6f ). To test model B, we again mutated residues predicted to participate in the Bax-vMIA interface E90 and D98 (Figure 7a ) and verified again that these constructs Bax(E90A)-GFP, Bax(D98A)-GFP and Bax(R89A, E90A, D98A)-GFP were expressed in cells at similar levels when transiently transfected (Figure 7a ). Transient transfection-enforced expression of these mutants induced cell death, both in control and in vMIA-expressing cells to a higher degree than that induced by WT Bax-GFP (Figure 7c-e) , indicating that the proapoptotic activity of Bax remained intact in these mutants and that vMIA could not protect cells against them. Although alanine substitutions of E90 and D98 (as well as simultaneous substitution of R89, E90 and D98 by alanines) did not abolish the proapoptotic action of Bax (Figure 7c and d) and did not affect the mitochondrial localization of the Bax protein (not shown), they did abrogate the interaction with vMIA in co-immunoprecipitation studies (Figure 7f ). These data are consistent with ) and 16 h after transfection were treated with 0.5 mg/ml anti-CD95 monoclonal antibody plus cyclohexamide 100 mg/ml for 8 h. Then, cells were stained with TMRME (150 nM) to determine the percentage of dying cells. The ability of vMIA to suppress apoptosis induced by each Bax mutant was calculated as compared to that with Bax WT, which was set to 100%. Error bars in (c-e) represent the mean7s.d. n ¼ 4. (f) Interaction between Bax mutants and vMIA. HeLa vMIA cells were transiently transfected with plasmids coding for Bax WT, Bax mutants or the corresponding empty vector (GFP). vMIA proteins were immunoprecipitated using an anti-Myc antibody and Bax proteins in the immunoprecipitated complexes were detected by immunoblotting with an anti-GFP antibody. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GFP, green fluorescent protein; PI, propidium iodide; TMRME, tetra methyl rhodamine methyl ester perchlorate; vMIA, viral mitochondria-localized inhibitor of apoptosis; WT, wild type. ) and 16 h after transfection were treated with 0.5 mg/ml anti-CD95 monoclonal antibody plus cyclohexamide 100 mg/ml for 8 h. Then, cells were stained with TMRME (150 nM) to determine the percentage of dying cells. The ability of vMIA to inhibit apoptosis induced by each Bax mutant was calculated as compared to that of Bax WT, which was set to 100%. Error bars in (d and e) represent the mean7s.d. n ¼ 3. (f) Interaction between Bax mutants and vMIA. HeLa vMIA cells were transiently transfected with plasmids coding for Bax WT, its mutants or the corresponding empty vector (GFP). vMIA proteins were immunoprecipitated using an anti-Myc antibody and Bax proteins in the immunoprecipitated complexes were detected by immunoblotting using an anti-GFP antibody. GFP, green fluorescent protein; TMRME, tetra methyl rhodamine methyl ester perchlorate; vMIA, viral mitochondria-localized inhibitor of apoptosis; WT, wild type. model B, in which vMIA docks to Bax in its membrane-inserted conformation, through an interaction that involves the BH2/3 interdomain of Bax.
Functional characterization of a dominant-negative vMIA mutant We examined if vMIAD131-147, lacking the BBD (and hence the interaction with Bax) might behave as a dominant-negative inhibitor of WT vMIA. vMIA exerts two separate effects on cells, the cytopathic phenomena (Poncet et al., 2006) , which do not require vMIA-Bax interaction, as shown with Bax-negative cells (Poncet et al., 2006) , and cell death suppression, which requires vMIA-Bax interaction (Arnoult et al., 2004; Poncet et al., 2004 ). First, we tested if vMIAD131-147 would induce cytopathic effects. We transiently transfected HeLa Neo cells with WT vMIAmyc, vMIAD131-147myc or an empty vector (Myc), and 24 h later examined these cells by immunofluorescence after staining them with antiMyc antibody (green fluorescence) and an antibody targeting mitochondria (red fluorescence). We found that vMIAD131-147 was similar to WT vMIA in its capacity to induce cytopathic effects, as indicated by the disruption of the mitochondrial network (Figure 8a ) and the disorganization of the actin cytoskeleton (Figure 8b ). We then examined the effects of vMIAD131-147 on apoptosis induced by STS, topoisomerase inhibition by etoposide or CD95 crosslinking in HeLa Neo control cells and HeLa vMIA cells. As expected (Hayajneh et al., 2001) , transiently transfected vMIAD131-147 did not suppress apoptosis in HeLa Neo cells (Figure 8c ). In addition, vMIAD131-147 restored the sensitivity of HeLa vMIA cells towards cell death induced by STS, etoposide and a-CD95 (Figure 8d ). In our attempt to identify the mechanism of this dominant-negative behavior of vMIAD131-147, we examined the ability of vMIA and vMIAD131-147 to pull down each over and also, separately or together, to pull down endogenous Bax, in immunoprecipitation assays with anti-Myc. We used vMIA and vMIAD131-147 C-terminally tagged with either Myc or GFP in these experiments. We found that vMIAD131-147 did not disrupt the interaction between Myc-tagged vMIA and endogenous Bax (Figure 8e ). Importantly, vMIA-GFP co-immunoprecipitated with vMIAmyc (Figure 8e ), indicating that vMIA forms dimers or higher-order oligomers. Accordingly, detergent-solubilized vMIA was detected as a higher-order molecular complex in native molecular sieve chromatography (Figure 8f ). vMIAmyc also immunoprecipitated with vMIAD131-147-GFP, although at a much lower level than with WT vMIA-GFP. Altogether, this information can be integrated into a model explaining how vMIAD131-147 acts as a dominant-negative mutant. While WT vMIA molecules associate into oligomers capable of cooperative or multivalent interactions with Bax, thus, forming a stable vMIA-Bax complex , mixed vMIA-vMIAD131-147 oligomers may have reduced number of valencies for Bax owing to either reduced stability of these complexes or a reduced number of WT vMIA molecules per oligomer, and as a result, would fail to inhibit the proapoptotic activity of Bax.
Discussion
In this investigation, we performed structure function analyses of the interaction between the proapoptotic endogenous protein Bax and the antiapoptotic CMVencoded protein vMIA. One particular difficulty in this study has been the absence of structural data on vMIA, a protein that has not yet been crystallized. Based on computerized secondary structure predictions and the available information on vMIA domains, we explored the possibility to fold vMIA into the conformation of Bcl-X L . This model yielded a plausible tertiary structure without major constraints and proved useful to model the interaction between vMIA and Bax. One important difference between vMIA and Bcl-X L , in functional terms, is that vMIA recruits Bax to mitochondria, causing its oligomerization and membrane insertion , while Bcl-X L functionally counteracts Bax, hindering it from inserting into the outer mitochondrial membrane Lang-Rollin et al., 2005) . This difference may be dictated by the nature of the Bax-vMIA and Bax-Bcl-X L interactions. Indeed, the BH3 domain of Bax is thought to bind to a hydrophobic cleft formed by the BH1, BH2 and BH3 domains of Bcl-X L (Suzuki et al., 2000) , while the BH3 domain of Bax is not involved in binding to vMIA, as shown here. Structural calculations and mutational analyses performed on the Bax protein indicate that the region of Bax that interacts with vMIA is located between the BH2 and BH3 domains. Interestingly, R89 and D98 of Bax are not conserved in Bak, suggesting the structural basis for the selective interaction of vMIA with Bax but not with Bak. An important notion that emerges from the computational calculations and experimental data is that vMIA binds tightly to membrane-inserted Bax, yet fails to interact with soluble Bax protein. This finding has implications for the mechanisms through which vMIA recruits Bax into mitochondrial membranes. On one hand, it is possible that vMIA first recruits soluble Bax through a transient interaction and then forces it into a membrane-inserted configuration. On the other hand it is possible that vMIA 'captures' Bax, once it has inserted into the outer mitochondrial membrane. As it stands, we prefer the latter model, because we have been unable to produce a plausible model of an interaction between vMIA and soluble Bax. However, the driving force for the membrane insertion of Bax that would precede its interaction with vMIA is currently not known. Speculatively, it may be linked to mitochondrial disorganization/dysfunction that is caused by the presence of vMIA.
We provide evidence that vMIA is not a monomer and rather constitutes an oligomer (and at least a dimer) in cells. It is tempting to speculate that the oligomerization of vMIA may be required for its recruitment of Bax and triggers oligomerization of Bax, perhaps by Our data confirm, at the structural level, that the bioenergetic and antiapoptotic effects of vMIA can be dissociated. vMIA mutants that fail to interact with Bax (including the dominant-negative vMIA construct) still induce fragmentation of the mitochondrial network and disorganization of the actin cytoskeleton. Clearly, the BBD is not required for vMIA dimerization, suggesting that the region of the molecule involved in homotypic interactions is different from that involved in heterotypic interactions by Bax, in line with the existence of mixed vMIA-Bax oligomers. The nature of the oligomerization domains of vMIA remains to be elucidated, and it remains to be clarified whether this oligomerization is linked to vMIA cytopathogenicity.
Irrespective of these speculative considerations, our analyses provide important insights into the physical and functional interaction between vMIA and Bax. Future will tell whether these structural insights can be taken advantage of to design small inhibitory molecules that antagonize the antiapoptotic function of vMIA for therapeutic purposes.
Materials and methods

Molecular modeling
The amino-acid sequence of vMIA (Hayajneh et al., 2001 ) was used as a query for profile and threading searches using PSIBlast (Altschul et al., 1997) , 3D-PSSM (Kelley et al., 2000) and GenThreader (McGuffin and Jones, 2003) . All the three different methods identified in Bcl-X L , a suitable structural template for vMIA. Based on the obtained sequence-tostructure alignment, three-dimensional models of vMIA were generated and optimized in an iterative manner using Modeller (Sali and Blundell, 1993) . The final vMIA model was subsequently docked to the experimental structure of Bax (Suzuki et al., 2000) employing 3D_Dock (Gabb et al., 1997) and the settings outlined in Table 1 . The resulting solutions were scored and clustered (Table 1) . Representatives of the top-ranked clusters were analysed further and optimized using Multidock (Jackson et al., 1998) and quick explore (QXP) (McMartin and Bohacek, 1997) .
Site-directed mutagenesis vMIA and Bax mutants were constructed using the QuickChange Site-Directed Mutagenesis Kit (Stratagene, Cedar Creek, NE, USA). vMIAmyc and Bax-GFP were used as templates for PCR amplification. vMIA WT and vMIAD131-147 were subcloned into pEGFP-N1 (Invitrogen, Carlsbad, CA, USA), so that GFP formed a C-terminal tag.
Cell culture, transfection and cell treatment Human HeLa cells, stably expressing vMIA (HeLa vMIA) or the empty vector pcDNA3myc (HeLa Neo) were cultured in Dulbecco's modified Eagle's medium media supplemented with 10% fetal calf serum, 100 U/ml penicilline, 100 mg/ml streptomycine, 10 mM N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid (HEPES), at 371C under 5% CO 2 . Transient transfections of HeLa cells with vectors coding for Myc-tagged vMIA WT or its deletion mutants, Bax-GFP fusion protein (kindly provided by Dr Shigemi Matsuyama (Matsuyama et al., 2000) ), and its mutants were performed using the Lipofectamine 2000 reagent (Invitrogen). For immunofluorescence, immunoblotting and flow cytometry analysis, transfections were performed in six-well plates using 2 ml lipofectamine for 3 mg plasmid. For immunoprecipitation, transient transfections were performed in 10-cm 2 cell culture dishes using 6 ml lipofectamine for 9 mg plasmid. To induce cell death, cells were treated with 0.5 mg/ml a-CD95 monoclonal antibody clone 7C11 (Immunotech, Marseille, France) plus 100 mg/ml cyclohexamide (Sigma, St Louis, MO, USA), with 50 nM STS (Sigma) or with 25 nM etoposide (Sigma) for the indicated periods of time.
Flow cytometry
To measure mitochondrial membrane potential, cells were incubated with 20 nM DiOC 6 (3) (3,3 0 -dihexyloxacarbocyanine iodide) or 150 nM TMRME (tetra methyl rhodamine methyl ester perchlorate, Molecular Probes, Leiden, The Netherlands), 20 min at 371C. To determine cell viability, cells were 
Immunofluorescence
Immunofluorescence experiments were performed as described (Castedo et al., 2002; Obeid et al., 2007) . vMIAmyc, actin filaments and DNA were visualized using a fluorescein isothiocyanate (FITC)-conjugated anti-Myc antibody (Abcam, Cambridge, UK), alexa fluor 568 conjugated Phalloidin (Invitrogen) and Hoechst 33342 (1 mg/ml, Invitrogen). The primary antibodies used were: anti-Myc (Santa Cruz, Santa Cruz, CA, USA) and anti-complex III core 2 (Invitrogen). Secondary Alexa Fluor-coupled antibodies were from Invitrogen. In most experiments, a Leica DMIRB (Leica DC200 camera, acquisition software Leica DC viewer) was used. Alternatively, a DMIR2 inverted fluorescence microscope (Leica DFC300FX, acquisition software Leica FW4000) was used.
Gel filtration analysis
Gel filtrations were performed at 41C on a Superdex 200 column (16/60 and 10/30, Amersham Biosciences, Orsay, France), as described before (Antonsson et al., 2001) . Briefly, the column was equilibrated in 25 nM HEPES-NaOH, 300 mM NaCl, 200 mM dithiothreitol, 2% (w/v) 3-((cholamidopropyl)-dimethylammonio)-1-propane sulfonate (CHAPS), pH7.5, and run at a flow rate of 1 ml/min. The column was calibrated with gel filtration standard proteins from Amersham Biosciences. Fractions of 2 ml were collected. The proteins present in these fractions were precipitated with trichloroacetic acid (10%) in water and subjected to immunoblot analysis.
Immunoprecipitation
Cells transiently transfected with vMIA and/or its mutants, Bax-GFP or its mutants and the corresponding empty vectors were used in these experiments. Cells were lysed in lysis buffer (150 mM NaCl, 20 mM Tris pH8, 5 mM NaF, 2 mM ethylenediaminetetraacetic acid, supplemented with 1% Triton X-100) in the presence of protease inhibitors for 30 min on ice and then centrifuged 30 min at 15 000 g to remove nuclei and cell debris. Supernatants were rotated 2 h at 41C with the anti-Myc antibody. For each point, 25 ml protein G sepharose beads were washed in lysis buffer five times before addition to the supernatants. After 1 h incubation, the beads were then washed five times in lysis buffer and the immunoprecipitated proteins were eluted by boiling.
Immunoblotting Cells were lysed in 0.1%. sodium dodecyl sulfate (SDS)-phosphate-buffered saline buffer, spun 5 min at 15 000 g. Total proteins (25 mg) were separated by SDS-polyacrylamide gel electrophoresis. The primary antibodies used were: anti-Myc (Santa Cruz), anti-Bax N-ter (Upstate, Charlottesville, VA, USA), anti-GAPDH, anti-Actin (Chemicon, Temecula, CA, USA), anti-GFP (JL8, Invitrogen). Secondary horseradish peroxidase (HRP)-conjugated antibodies were from Southern Biotechnologies (Birmingham, AL, USA) except for immunodetection of immunoprecipitated proteins for which secondary HRP-conjugated antibodies from eBiosciences (San Diego, CA, USA) were used.
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